153 related articles for article (PubMed ID: 36761970)
1. Case report: A rare case of sintilimab-induced gastric stenosis and literature review.
Song K; Dong H; Jiang S; Xu X; Zhang C; Chen Q; Wang Q
Front Oncol; 2023; 13():1091459. PubMed ID: 36761970
[TBL] [Abstract][Full Text] [Related]
2. Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.
Yan J; Ma N; Qiao WL; Liu KQ; Liu DW; Wang Y; Qiao TT; Hao XQ; Zheng MD
Ann Transl Med; 2022 Dec; 10(24):1411. PubMed ID: 36660611
[TBL] [Abstract][Full Text] [Related]
3. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.
Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J
J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597
[TBL] [Abstract][Full Text] [Related]
4. Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review.
Liu X; Zeng Z; Cao J; Li X; Muhetaer M; Jin Z; Cai H; Lu Z
J Cardiovasc Dev Dis; 2023 Oct; 10(10):. PubMed ID: 37887869
[TBL] [Abstract][Full Text] [Related]
5. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
6. Corneal ulcer development due to sintilimab-anlotinib combination therapy-induced dry eye: a case report.
Xiang X; Lin W; Guan X; Zhou B; Yuan Y; Silva D; Wang Y
Transl Cancer Res; 2024 May; 13(5):2571-2579. PubMed ID: 38881937
[TBL] [Abstract][Full Text] [Related]
7. A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Zhou L; Xiong Y; Wang Y; Meng Y; Zhang W; Shen M; Zhang X; Li S; Ren B; Li R; Han Y; Zhang J; Cao S; Du W; Sun Q; Wei F; An X; Yang L; Zhang Y; Ma W; Xu W; Zhang Y; Jiang J; Xu X; Xia J; Liu L; Ren X
Clin Lung Cancer; 2022 Dec; 23(8):709-719. PubMed ID: 35995696
[TBL] [Abstract][Full Text] [Related]
8. A rare presentation of Sintilimab-induced swelling along the vessels: Case report.
Liu L; Yu Y; Xia J; Ning Y
Medicine (Baltimore); 2023 May; 102(21):e33859. PubMed ID: 37233405
[TBL] [Abstract][Full Text] [Related]
9. Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review.
Yang Y; Xu H; Zhang L; Bai L; Zhu H; Li Q
Anticancer Drugs; 2022 Feb; 33(2):214-219. PubMed ID: 34620744
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab for the treatment of non-small cell lung cancer.
Zhang L; Lin W; Tan F; Li N; Xue Q; Gao S; Gao Y; He J
Biomark Res; 2022 Apr; 10(1):23. PubMed ID: 35436956
[TBL] [Abstract][Full Text] [Related]
11. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
Ding P; Guo H; Sun C; Yang P; Kim NH; Tian Y; Liu Y; Liu P; Li Y; Zhao Q
BMC Gastroenterol; 2022 Mar; 22(1):121. PubMed ID: 35287591
[TBL] [Abstract][Full Text] [Related]
12. Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events.
Tu L; Ye Y; Tang X; Liang Z; You Q; Zhou J; Pan Z
Front Oncol; 2021; 11():757069. PubMed ID: 35004277
[TBL] [Abstract][Full Text] [Related]
13. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
Ai Q; Chen W; Li Y; Li G
Front Immunol; 2022; 13():840916. PubMed ID: 35720298
[TBL] [Abstract][Full Text] [Related]
14. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
15. Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series.
Fan BS; Wang XT; Di SY; Zhao JH; Chen SY; Zhou SH; Yue CY; Song WA; Gong TQ
Transl Cancer Res; 2022 Jun; 11(6):1697-1704. PubMed ID: 35836545
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review.
Wang J; Xiao X; Dong X; Wu G; Wang X; Zhang R
Front Oncol; 2022; 12():931074. PubMed ID: 36016624
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer.
Xie J; Wu X; Wu J; Huang F; Xu L
Oncol Lett; 2022 Dec; 24(6):425. PubMed ID: 36284649
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review.
Zhang L; Wu Z
Clin Cosmet Investig Dermatol; 2023; 16():457-461. PubMed ID: 36846442
[TBL] [Abstract][Full Text] [Related]
19. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
Mei Y; Shi M; Zhu Z; Yuan H; Yan C; Li C; Feng T; Yan M; Zhang J; Zhu Z
Future Oncol; 2022 Jan; 18(2):139-148. PubMed ID: 34877867
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial.
Wei J; Lu X; Liu Q; Fu Y; Liu S; Li L; Liu F; Fan X; Yang J; Yang Y; Zhao Y; Guan W; Liu B
Cancer Manag Res; 2022; 14():2007-2015. PubMed ID: 35747712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
